Control of Symptoms in Patients with Me´nie`re's Disease Using Middle Ear Pressure Applications: Two Years Follow-up
Control of Symptoms in Patients with Me´nie`re's Disease Using Middle Ear Pressure Applications: Two Years Follow-up
复制标题
使用中耳压力应用控制梅尼埃病患者的症状：两年随访
DOI：
10.1080/oto.121.5.616.621
复制
发表时间：
2001
影响因子：
1.4
通讯作者：
B. Densert
中科院分区：
文献类型：
--
作者：
K. Sass;B. Densert
研究人员对 37 名确诊患有梅尼埃病和活动性前庭症状的患者进行了中耳压力脉冲的影响研究，其中 31 名患者在压力治疗前对包括利尿剂在内的药物治疗没有反应。评估治疗前6个月以及治疗开始后6、18和24个月期间眩晕发作的次数。根据美国耳鼻咽喉头颈外科学会 (AAO-HNS) 标准，功能水平评分为 3 或更差。研究结果如下： 19 名患者不再出现眩晕症状； 15 名患者报告眩晕发作频率显着降低； 3名患者对压力治疗没有反应，接受庆大霉素注射，其中1名患者患耳失聪。没有患者因压力治疗而病情恶化。除了对压力治疗没有反应的三名患者外，根据 AAO-HNS 功能量表，所有患者均报告功能至少提高了两个水平。在2年的压力治疗期间没有观察到副作用或不良事件。总体而言，结果表明压力治疗可以有效控制顽固性梅尼埃病患者的症状，而不会对内耳产生任何不利影响。
The effects of middle ear pressure pulses were studied in 37 patients with a diagnosis of definite Ménière's disease and active vestibular symptoms, 31 of whom had failed to respond to medical treatment including diuretics prior to pressure treatment. The number of vertigo spells during the 6 months prior to treatment and for 6, 18 and 24 months after the start of treatment were evaluated. The functionality level scores were three or worse according to the American Academy of Otolaryngology?Head and Neck Surgery (AAO-HNS) criteria. The results of the study were as follows: 19 patients experienced freedom from vertigo spells; 15 patients reported a significant decrease in the frequency of vertigo spells; and 3 patients did not respond to pressure treatment and were subjected to gentamicin injections, 1 of whom consequently became deaf in the affected ear. No patient became worse in connection with pressure treatment. With the exception of the three patients who did not respond to pressure treatment, all patients reported an improvement in functionality of at least two levels according to the AAO-HNS functionality scale. No side effects or adverse events were observed during the 2 years of pressure treatment. Overall, the results indicate that pressure treatment provides efficient control of symptoms in patients with intractable forms of Ménière's disease without producing any adverse effects on the inner ear.